Parametric Portfolio Associates LLC Has $12.12 Million Stake in Elanco Animal Health (NYSE:ELAN)

Parametric Portfolio Associates LLC increased its holdings in shares of Elanco Animal Health (NYSE:ELAN) by 71.5% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 358,532 shares of the company’s stock after purchasing an additional 149,473 shares during the quarter. Parametric Portfolio Associates LLC owned approximately 0.10% of Elanco Animal Health worth $12,118,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ELAN. Primecap Management Co. CA lifted its stake in Elanco Animal Health by 516.8% in the first quarter. Primecap Management Co. CA now owns 30,607,906 shares of the company’s stock valued at $981,596,000 after acquiring an additional 25,645,707 shares during the last quarter. BlackRock Inc. lifted its stake in Elanco Animal Health by 618.1% in the first quarter. BlackRock Inc. now owns 19,559,113 shares of the company’s stock valued at $627,262,000 after acquiring an additional 16,835,410 shares during the last quarter. Lazard Asset Management LLC acquired a new stake in Elanco Animal Health in the first quarter valued at $341,261,000. OppenheimerFunds Inc. acquired a new stake in Elanco Animal Health in the first quarter valued at $310,058,000. Finally, American Century Companies Inc. lifted its stake in Elanco Animal Health by 327.2% in the first quarter. American Century Companies Inc. now owns 8,875,571 shares of the company’s stock valued at $284,640,000 after acquiring an additional 6,797,761 shares during the last quarter.

In related news, Director Deborah Turner Kochevar bought 1,000 shares of the business’s stock in a transaction dated Wednesday, September 11th. The stock was bought at an average price of $27.95 per share, for a total transaction of $27,950.00. Also, insider Todd S. Young bought 10,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The shares were bought at an average price of $26.57 per share, with a total value of $265,700.00. Following the purchase, the insider now owns 28,883 shares in the company, valued at approximately $767,421.31. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 112,780 shares of company stock valued at $3,003,162. 0.04% of the stock is currently owned by corporate insiders.

A number of brokerages have commented on ELAN. UBS Group upgraded shares of Elanco Animal Health from a “sell” rating to a “neutral” rating and cut their price target for the company from $31.00 to $30.00 in a research note on Thursday, August 15th. Zacks Investment Research cut shares of Elanco Animal Health from a “hold” rating to a “sell” rating in a research note on Friday, September 6th. Goldman Sachs Group began coverage on shares of Elanco Animal Health in a research note on Monday, September 9th. They issued a “positive” rating for the company. They noted that the move was a valuation call. Bank of America cut shares of Elanco Animal Health from a “buy” rating to a “neutral” rating and set a $30.00 price target for the company. in a research note on Monday, August 26th. Finally, Barclays began coverage on shares of Elanco Animal Health in a research note on Monday. They issued an “overweight” rating and a $36.00 price target for the company. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $33.98.

Shares of NYSE ELAN traded up $0.44 during mid-day trading on Monday, reaching $27.97. 3,709,882 shares of the company were exchanged, compared to its average volume of 4,085,792. The company’s 50-day simple moving average is $28.53 and its 200-day simple moving average is $31.49. The company has a quick ratio of 1.71, a current ratio of 3.07 and a debt-to-equity ratio of 0.45. The stock has a market capitalization of $9.92 billion and a P/E ratio of 23.70. Elanco Animal Health has a twelve month low of $25.51 and a twelve month high of $37.61.

Elanco Animal Health (NYSE:ELAN) last posted its earnings results on Tuesday, August 13th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.02. The company had revenue of $781.60 million during the quarter, compared to analysts’ expectations of $781.49 million. Elanco Animal Health had a net margin of 4.69% and a return on equity of 7.83%. The business’s quarterly revenue was up 1.5% on a year-over-year basis. As a group, equities research analysts expect that Elanco Animal Health will post 1.08 EPS for the current year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

See Also: Market Capitalization – What it Means for Investors

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.